Mylan Institutional LLC is recalling 19,165 vials of Rifampin for Injection, USP (600 mg/vial). This prescription antibiotic was found to have discoloration caused by elevated levels of an unknown impurity that failed quality specifications. This chemical degradation can decrease the effectiveness of the medication, potentially failing to treat the underlying infection as intended. Consumers should contact their healthcare provider or pharmacist for guidance on alternative treatments and return any unused product to their pharmacy for a refund.
The presence of elevated impurities indicates the drug is degrading, which can reduce the potency and effectiveness of the antibiotic treatment. If the medication does not work correctly, the patient's infection may not be properly treated, leading to worsened health outcomes.
Healthcare provider consultation and pharmacy refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.